Anti-CD28 Monoclonal Antibody Therapy Prevents Chronic Rejection of Renal Allografts in Rats

Reduction of chronic rejection of renal allografts by anti-transforming growth factor-β antibody therapy in a rat model.

There is no effective treatment for chronic rejection (CR) that largely limits long-term survival of kidney transplants. Transforming growth factor (TGF)-β is a fibrogenic factor for tissue fibrosis. This study was to test the efficacy of an anti-TGF-β antibody in preventing the CR of renal allografts in a preclinical model. Male Lewis rats (RT1¹) were orthotopically transplanted with donor kid...

Antibody-mediated rejection in renal allografts: lessons from pathology.

The past 15 years have seen major advances in the understanding of the effects of anti-donor antibodies on renal allografts at various stages after transplantation. These advances have been due in large part to pathologic examination of both early and late renal allograft biopsies, including both routine histologic evaluation and immunohistology to detect complement split products. As pathologi...

Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.

Eight cadaver donor renal allograft recipients, who had received azathioprine and prednisone from the day of transplantation, were treated with OKT3 monoclonal antibody (reactive with all mature peripheral blood T cells) at the time of diagnosis of acute rejection. In all cases, loss of essentially all detectable peripheral blood OKT3-reactive cells was noted within minutes after the initial 1-...

The anti-apoptotic effect of ghrelin in the renal tissue of chronic hypoxic rats

Introduction: Ghrelin is an endogenous peptide that has diverse functions in the body. One of the newly recognized roles of this peptide is its antiapoptotic effect. However, this function has not been investigated in normobaric hypoxia- induced apoptosis in body organs. This study will examine the effect of ghrelin treatment on Bax-Bcl-2 gene expression in the kidney of chronic hypoxic rats. ...

Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody